ADIA Nutrition Inc. (ADIA) reports developments tied to its regenerative medicine, stem cell therapy, and biologic products business. The company operates through Adia Med clinics, which offer treatments such as PRP, AHSCT, orthopedic care, pain management, and wound repair, and through Adia Labs, which develops and sells biologic products including AdiaVita and AdiaLink.
Company news commonly covers clinical and regulatory activity involving AdiaVita, including study programs in chronic kidney disease, autism spectrum disorder, and chronic lower back pain. Updates also address operating results, product sales and medical-service revenue, capital-structure disclosures, governance matters, and the company's transition from a supplement-oriented business toward regenerative healthcare.
Adia Med (OTCQB: ADIA), a clinical-stage regenerative medicine company, has launched a redesigned corporate website at www.adiamed.com, which now serves as its primary digital hub following the recent name change from Adia Nutrition to Adia Med.
The site highlights clinical studies, stem cell therapies, and aesthetics, and includes or is planned to include sections for media coverage, podcasts and video interviews, clinical case studies, investor information and regulatory filings, company news, and educational resources. The former site, www.adianutrition.com, now automatically redirects to the new platform, which the company says is still being enhanced and aims to improve transparency and accessibility for patients, healthcare professionals, media, and investors.
Adia Med (OTCQB: ADIA) outlines milestones since its January 2024 leadership change, when Larry Powalisz became CEO and bootstrapped a new regenerative medicine strategy. The company acquired and later divested Biolete, secured an 18% stake in Cement Factory, created subsidiaries Adia Med of Winter Park and Adia Labs, and removed its shell status effective June 30, 2024.
By January 2025, Adia Med opened its flagship Winter Park clinic, began treating patients, and in May 2025 retired over 25 million improperly issued shares via court settlement. According to Adia Med, revenue reached $637,145 in the first nine months of 2025, driven by biologics and clinic procedures. The company gained FDA registration for its biologics, filed a provisional patent, and was uplisted to the OTCQB Venture Market in 2025.
Adia Med obtained IRB approvals and ClinicalTrials.gov registration for autism spectrum disorder (ASD), chronic kidney disease, and lower back pain studies, with ASD treatments starting May 1, 2026. With Form 10 effective on February 3, 2026 and a name change advancing through FINRA, the company targets a future NASDAQ uplisting, citing remaining shareholder equity and net revenue requirements.
Adia Nutrition (OTCQB: ADIA) will begin trading as Adia Med Inc. following an expedited FINRA review of its corporate name change. The new name appears on the FINRA Daily List today, with trading under Adia Med Inc. expected to start July 10, 2026, on OTC Markets.
According to the company, the new name aligns with its focus on stem cell and regenerative therapies.
Adia Nutrition (OTCQB: ADIA) announced it has entered the final stage of its corporate name change process to Adia Med. After several months of FINRA review and three comment rounds, the company believes all requirements are satisfied and expects FINRA approval in the coming weeks.
Adia Med (OTCQB: ADIA) highlighted a new podcast where CEO Larry Powalisz interviews Dr. Lyday, a physician known for supporting stem cell-based treatments. Powalisz calls her a clinical "unicorn" who both researches and applies regenerative medicine.
The discussion covers stem cells, exosomes, clinical uses for conditions including Lyme disease, safety issues, and the future of regenerative medicine, aligning with Adia Med’s mission and its AdiaVita product line. The full episode is available on YouTube.
Adia Med (OTCQB: ADIA) is enhancing IV therapy quality by having Lead Physician Dr. Brian Browning train APRNs and RNs in ultrasound-guided IV insertions using the Butterfly portable ultrasound device.
The program targets more precise, reliable, and comfortable IV access, especially for patients with difficult veins, and supports Adia Med’s regenerative and nutrient therapies, including stem cell, exosome, glutathione, and other precision wellness infusions.
Adia Nutrition (OTCQB: ADIA) has received State of Nevada approval to change its corporate name to Adia Med Inc.
The change reflects a focus on advanced medical and wellness solutions, including active clinical studies, a research pipeline at Adia Labs, and distribution of stem cell and exosome products. Trading symbol and CUSIP will remain unchanged, pending FINRA review.
Adia Nutrition (OTCQB: ADIA) launched wholly owned subsidiary ADIA Life LLC, headquartered in Florida, to centralize distribution of Adia Labs products and manage a nationwide distributor network.
The unit will streamline logistics and support future consumer programs in nutrition, fitness, mindset coaching and broader wellness solutions within the $4.5 trillion global wellness industry.
Adia Nutrition (OTCQB: ADIA) announced a nearly completed documentary featuring TNA Wrestling star Jeff Sciullo, known as Elias, highlighting his recovery from a severe tricep tendon tear.
The film follows his comeback after surgery and an AdiaVita stem cell and exosome infusion, showing accelerated healing and return to performance.
Adia Nutrition (OTCQB: ADIA) announced that an independent monthly-membership health care sharing ministry now accepts up to three stem cell treatments per client as an alternative to traditional insurance coverage.
The ministry serves over 250,000 members nationwide, expanding access to Adia’s regenerative therapies such as AdiaVita through affiliate clinics.